Baxter International Value Stock - Dividend - Research Selection
Market price: 65,11 USD
Baxter International Fundamental data and company key figures of the share
|Annual reports in USD|
|Net operating cash flow||2.222.000.000|
|Free cash flow||1.479.000.064|
|Liabilities & Shareholders equity||33.521.000.000|
|Diluted shares outstanding||506.000.000|
✓ NEW Fundamental API Access to 500 data points per month
✓ Fundamental data up to 25 years
✓ Comparison to all other stocks by the FScore
✓ Time saving!
How our site works ...
✓ Non-binding 7 days without automatic subscription
✓ No termination required after the free week
✓ Finanzoo fundamental analysis
✓ Data updated daily
✓ Virtual depots
✓ Share alarms via email
✓ Subscription can be canceled at any time at the end of the month
✓ Choice of desired shares
✓ Over 2000 stock analyzes available
✓ Bitcoin payment possible if you do not want to subscribe
Price for monthly subscription $ 19.99 / month including VAT.
|Market Capitalization||32.945.659.904,00 USD|
|Indices||MSCI World Index,S&P 500|
|Sectors||Health Care Equipment|
|Raw Data Source||US GAAP in Millionen USD|
|Stock Split||2015-07-01,1841.0000/1000.0000; 2001-05-31,2.0000/1.0000; 1992-12-01,100000.0000/90823.0000; 1983-11-18,2.0000/1.0000; 1981-11-09,1.0000/2.0000; 1981-11-04,2.0000/1.0000|
Description of the company
Baxter International Inc. (Baxter,) is a global, diversified healthcare company. Baxter, through its subsidiaries, develops, manufactures and markets products that save and sustain the lives of people with hemophilia, immune disorders, infectious diseases, kidney disease, trauma, and other chronic and acute medical conditions. The Company operated in two segments: BioScience and Medication Delivery. It is engaged in the medical devices, pharmaceuticals and biotechnology to create products that advance patient care worldwide. These products are used by hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, doctors' offices, clinical and medical research laboratories, and by patients at home under physician supervision. Baxter manufactures products in 27 countries and sells the products in more than 100 countries. In September 2013, Baxter International Inc completed the acquisition of Gambro AB.